Filing Analysis
Lyell Immunopharma, Inc. filed an 8-K to announce the release of its financial results for the quarter ended June 30, 2026.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Quarter ended June 30, 2026.
- Filing date: August 6, 2026.
- The information provided under Item 2.02 is furnished but not filed for purposes of Section 18 liability.
Lyell Immunopharma presented new clinical and translational data for its dual-targeting CAR T-cell product, ronde-cel (LYL314), at the 67th ASH Annual Meeting. The data covers patients with large B-cell lymphoma (LBCL) across both 2L and 3L+ settings, demonstrating high response rates and a manageable safety profile.
🚩 Red Flags
- None identified in this clinical update.
📋 Key Facts
- Clinical trial evaluated 69 total patients; efficacy evaluable population was 47 patients (29 in 3L+ setting, 18 in 2L setting).
- In the 3L+ setting: 93% Overall Response Rate (ORR) and 76% Complete Response (CR) rate; median progression-free survival of 18 months.
- In the 2L setting: 83% ORR and 61% CR rate; 94% of patients had primary refractory disease.
- Safety profile showed no Grade 3 or greater cytokine release syndrome (CRS) observed in any patient.
- Only one case (4%) of Grade 3 or greater ICANS was reported among the 69 patients.
- Translational data indicated ronde-cel achieved up to a three-fold higher expansion post-infusion compared to approved CD19 CAR T-cell products.
Lyell Immunopharma, Inc. has amended and restated its Bylaws to modernize stockholder proposal procedures and ensure compliance with Delaware General Corporation Law.
📋 Key Facts
- The Board of Directors amended and restated the Company's Amended and Restated Bylaws effective December 3, 2025.
- Changes include modernized stockholder proposal disclosure requirements regarding director nominations.
- Updates clarify that significant changes to previously submitted proposals will be treated as new proposals rather than updates.
- Bylaws were updated to conform with Section 232 and Section 219 of the Delaware General Corporation Law (DGCL).
Lyell Immunopharma, Inc. filed an 8-K to announce its financial results for the quarter ended September 30, 2025. The filing serves as a formal announcement of the earnings release via Exhibit 99.1.
📋 Key Facts
- Report date: November 12, 2025
- Reporting period: Quarter ended September 30, 2025
- The filing includes a press release as Exhibit 99.1 regarding financial results.
Lyell Immunopharma entered into an exclusive worldwide license agreement (excluding Greater China) with the ICT Group to exploit certain product candidates. The deal involves significant upfront cash, equity issuance, and substantial contingent milestone payments.
🚩 Red Flags
- Significant cash outflow ($40M) and equity dilution (3.75 million total potential shares) for a micro/mid-cap biotech
- Large contingent liabilities (up to $820M in combined milestones) which could impact future cash flows if triggered
📋 Key Facts
- Effective Date: November 6, 2025
- Upfront Cash Payment: $40 million to ICT Holdings
- Immediate Equity Issuance: 1.9 million shares of Lyell common stock to ICT Holdings
- Clinical Milestone: Potential $30 million payment upon achievement of specific milestones
- Regulatory Milestones: Up to $115 million in contingent payments based on late-stage regulatory achievements
- Commercial Sales Milestones: Up to $675 million based on annual net sales
- Equity Contingency: Up to 1.85 million additional shares issuable upon clinical/regulatory milestones
- Royalties: Mid-single digits up to 10% in the US; low to mid-single-digit royalties internationally
Lyell Immunopharma, Inc. announced leadership changes effective October 31, 2025, involving the appointment of interim financial officers following a vacancy in key finance roles.
🚩 Red Flags
- CEO is assuming dual roles (CEO and interim PFO), which can indicate internal instability or a sudden departure of the previous CFO.
- Concentration of executive responsibility in the CEO during a transition period.
📋 Key Facts
- Effective October 31, 2025, Dr. Lynn Seely (President and CEO) was appointed as the Company's interim principal financial officer.
- Veronica Sanchez Bulis (VP, Corporate Controller) was appointed as the Company's principal accounting officer.
- The appointment of the interim PFO by the CEO suggests a sudden vacancy in the CFO position.
Lyell Immunopharma, Inc. announced the resignation of its Chief Financial Officer (CFO) and principal financial and accounting officer, Charles Newton, effective October 31, 2025. The departure is not due to any disagreements with the company.
🚩 Red Flags
- Departure of a key executive (CFO) can create temporary leadership instability and administrative transition risks.
📋 Key Facts
- Charles Newton resigned as CFO and principal financial/accounting officer on September 15, 2025.
- The resignation becomes effective on October 31, 2025.
- No disagreements between Mr. Newton and the Company were reported.
- Mr. Newton will enter into a consulting agreement through April 30, 2026, to provide services following his departure.
Lyell Immunopharma, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2025. The filing serves as a formal notification that earnings data was released via press release on August 12, 2025.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2025.
- Filing date: August 12, 2025.
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
Lyell Immunopharma entered into a Securities Purchase Agreement for a private placement of common stock and pre-funded warrants totaling approximately $50 million in initial gross proceeds. The agreement includes complex milestone-based provisions that allow the company to require additional funding or allow investors to exercise call rights based on clinical trial outcomes.
🚩 Red Flags
- Complex milestone-based financing structure creates significant dilution risk if clinical milestones are met.
- The 'Milestone Closing Put Right' effectively forces investors to provide more capital upon success, which can be highly dilutive at the $25.61 strike price.
📋 Key Facts
- Initial closing anticipated on or about July 25, 2025.
- Initial offering: 3,753,752 shares of Common Stock at $13.32 per share for ~$50.0 million in gross proceeds.
- Milestone Closing Put Right: Company can require investors to purchase an additional ~$50.0 million if clinical milestones (LYL314 PiNACLE trial) or corporate milestones are met within 12 months.
- Milestone price set at $25.61 per share (with a floor of $10.41).
- Investor Call Closing: Investors have the right to purchase an additional ~$50.0 million at $30.73 per share.
- Pre-funded warrants issued to avoid exceeding 9.99%/19.99% beneficial ownership thresholds; exercise price of $0.0001.
- Company expects cash runway to extend into mid-2027 following the initial closing.
Lyell Immunopharma has announced the achievement of clinical milestones by ImmPACT Bio USA Inc., triggering the issuance of 625,000 shares of common stock to ImmPACT securityholders via private placement.
🚩 Red Flags
- Issuance follows a recent 1-for-20 reverse stock split (May 30, 2025), which often indicates significant share price distress or delisting avoidance efforts.
- The shares are being issued via private placement without registration.
📋 Key Facts
- Achievement of clinical milestones for ImmPACT's next-generation CAR T-cell product candidate as of June 20, 2025.
- Issuance of 625,000 shares of Company Common Stock to ImmPACT securityholders via private placement.
- The issuance follows a 1-for-20 reverse stock split that was previously effected on May 30, 2025.
- The sale is being conducted under the Section 4(a)(2) exemption of the Securities Act.
Lyell Immunopharma announced positive clinical data from its Phase 1/2 trial of LYL314, a dual-targeting CD19/CD20 CAR T-cell product, showing high response rates in patients with large B-cell lymphoma (LBCL). The company also provided updates on manufacturing capacity and upcoming clinical trial timelines.
🚩 Red Flags
- None identified in this clinical update filing.
📋 Key Facts
- LYL314 showed an 88% overall response rate (ORR) in the 3L+ efficacy-evaluable population (N=25) with a 72% complete response (CR) rate.
- In the 2L setting, LYL314 demonstrated a 91% ORR and 64% CR rate in an initial cohort of 11 patients.
- Safety profile was described as manageable; no deaths were related to LYL314 administration and Grade ≥ 3 cytokine release syndrome (CRS) was not reported.
- The company expects to initiate a randomized pivotal trial for the 2L setting by early 2026.
- Manufacturing capacity at the LyFE Manufacturing Center is expected to support over 1,200 doses annually upon full staffing.
Lyell Immunopharma, Inc. announced the appointment of Mark Bachleda, Pharm.D., M.B.A. to its Board of Directors as a Class I director, increasing the board size from seven to eight members.
🚩 Red Flags
- The filing references a 1-for-20 reverse stock split effective May 30, 2025, which is often a sign of extreme share price volatility or delisting risk (though not explicitly stated as a notice here).
📋 Key Facts
- Appointment of Mark Bachleda, Pharm.D., M.B.A. to the Board of Directors effective June 9, 2025.
- Board size increased from seven to eight directors.
- Dr. Bachleda's term expires at the Company’s annual meeting of stockholders in 2028.
- Compensation for Dr. Bachleda will be adjusted for a recent 1-for-20 reverse stock split that became effective on May 30, 2025.
Lyell Immunopharma, Inc. has filed a Certificate of Amendment to effect a 1-for-20 reverse stock split, effective May 30, 2025. The split aims to consolidate outstanding shares from approximately 296 million down to roughly 14.8 million.
🚩 Red Flags
- Reverse stock split (often used to maintain Nasdaq listing requirements or signal distress).
- Significant reduction in share count (95% reduction) which can lead to increased volatility and potential dilution if new equity is issued at higher prices later.
📋 Key Facts
- Reverse stock split ratio of 1-for-20.
- Effective Date: May 30, 2025, at 5:00 p.m. ET.
- New trading begins on Nasdaq Global Select Market on a split-adjusted basis on June 2, 2025.
- Pre-split outstanding shares: 296,161,570; Post-split estimated shares: ~14,808,078.
- New CUSIP number: 55083R203.
- Fractional shares will be paid out in cash.
Lyell Immunopharma held its 2025 annual meeting of stockholders where shareholders approved a series of alternate amendments to effect a reverse stock split. The proposed ratio ranges from 1-for-10 to 1-for-25, at the discretion of the Board.
🚩 Red Flags
- Approval of a significant reverse stock split (up to 1-for-25) is often used to boost share price to meet exchange listing requirements or improve market perception, which can be a sign of distress in micro-cap/small-cap biotech companies.
📋 Key Facts
- Annual Meeting held virtually on May 15, 2025.
- Quorum established with 212,358,298 shares (71.9% of outstanding shares) represented.
- Catherine Friedman was elected to the Class I director position.
- Ernst & Young LLP was ratified as independent auditors for FY2025.
- Shareholders approved a reverse stock split ratio between 1-for-10 and 1-for-25.
Lyell Immunopharma, Inc. filed an 8-K to announce its financial results for the fiscal quarter ended March 31, 2025.
📋 Key Facts
- Report date: May 13, 2025
- Period covered: Quarter ended March 31, 2025
- The filing is a standard announcement of quarterly financial results via press release (Exhibit 99.1).
Lyell Immunopharma is closing its West Hills manufacturing facility acquired via the ImmPACT Bio merger and reducing its workforce by approximately 73 employees. The company expects to incur $3.0M-$4.0M in one-time closure costs but maintains a cash runway into 2027.
🚩 Red Flags
- Significant workforce reduction (73 employees) following a recent acquisition (ImmPACT Bio).
- High cash burn rate: $175M-$185M projected for 2025.
- Resignation of Chief Business Officer Matthew Lang, effective April 13, 2025.
📋 Key Facts
- Closure of West Hills manufacturing facility approved on March 31, 2025.
- Workforce reduction of approximately 73 employees at the West Hills site.
- Estimated one-time expenses for closure and severance: $3.0 million to $4.0 million.
- Expected recognition of costs in Q2 and Q3 2025.
- LyFE manufacturing center in Bothell, WA will handle IMPT-314 production for Phase 1/2 trials and potential commercial launch.
- Projected 2025 net cash use: $175 million - $185 million.
- Cash runway expected to extend into 2027.
Lyell Immunopharma, Inc. has filed an 8-K to announce its financial results for the quarter and full year ended December 31, 2024.
📋 Key Facts
- Report date: March 11, 2025
- Reporting period: Quarter and Full Year ended December 31, 2024
- The filing is pursuant to Item 2.02 (Results of Operations and Financial Condition)
- Financial results were released via press release attached as Exhibit 99.1
Lyell Immunopharma received a notice from Nasdaq stating that its common stock has been below the $1.00 minimum bid price for 33 consecutive business days. The company has until July 22, 2025, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq (Rule 5450(a)(1))
- Potential requirement for a reverse stock split to regain compliance
- Risk of transfer from Nasdaq Global Select Market to Nasdaq Capital Market if second compliance period is required
📋 Key Facts
- Received notice from Nasdaq Listing Qualifications Staff on January 23, 2025.
- The bid price closed below $1.00 for the last 33 consecutive business days.
- Compliance deadline (Compliance Date) is July 22, 2025.
- To regain compliance, the stock must maintain a closing bid price of at least $1.00 for 10 consecutive business days prior to the Compliance Date.
- The company may be eligible for an additional 180-day second compliance period if it transfers to The Nasdaq Capital Market.
Lyell Immunopharma, Inc. has filed an amendment to its previous 8-K to provide the required audited and unaudited financial statements and pro forma information following its acquisition of ImmPACT Bio USA Inc., which closed on October 31, 2024.
🚩 Red Flags
- The filing is an amendment to a previous 8-K, indicating a delay in providing required post-acquisition financial data (though within the allowed 71-day window).
📋 Key Facts
- Acquisition of ImmPACT Bio USA Inc. closed on October 31, 2024.
- The filing includes audited financial statements for ImmPACT as of and for the fiscal year ended December 31, 2023 (Exhibit 99.1).
- Includes unaudited financial statements for ImmPACT for the nine months ended September 30, 2024 (Exhibit 99.2).
- Provides unaudited pro forma condensed combined balance sheet and statements of operations as of September 30, 2024, and fiscal year ended December 31, 2023 (Exhibit 99.3).
- Includes consent from Deloitte & Touche LLP regarding the audited financial statements.
Lyell Immunopharma issued a press release regarding positive initial clinical data from its Phase 1-2 trial of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product, presented at the ASH Annual Meeting.
📋 Key Facts
- Clinical data pertains to IMPT-314 in patients with large B-cell lymphoma.
- IMPT-314 is a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate.
- The trial aims to increase complete response rates and prolong response duration compared to current approved therapies.
- Data was presented at the 66th American Society of Hematology (ASH) Annual Meeting.
Lyell Immunopharma announced the resignation of Hans Bishop from the Board of Directors and the Nominating and Corporate Governance Committee, effective November 22, 2024.
📋 Key Facts
- Hans Bishop resigned as a member of the Board of Directors on November 22, 2024.
- Mr. Bishop also resigned from the Nominating and Corporate Governance Committee.
- The company explicitly stated that the resignation was not due to any disagreement or dispute with the Company.
Lyell Immunopharma, Inc. filed an 8-K to announce its financial results for the quarterly period ended September 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Quarter ended September 30, 2024.
- Filing date: November 7, 2024.
Lyell Immunopharma completed its acquisition of ImmPACT Bio USA Inc. on October 31, 2024. The transaction includes a combination of cash and equity, along with contingent consideration tied to clinical and regulatory milestones.
🚩 Red Flags
- Significant dilution potential due to 37.5 million shares issued plus up to 12.5 million contingent shares.
- Registration Rights Agreement entered into, allowing sellers to file shelf registration statements for resale of LYEL stock.
📋 Key Facts
- Acquisition closed on October 31, 2024.
- Upfront payment consisted of $30.0 million in cash (adjusted by ~$12.0 million for ImmPACT's existing cash) and 37.5 million shares of LYEL common stock.
- Contingent consideration includes up to 12,500,000 additional shares of LYEL upon clinical or regulatory milestones.
- Includes a low single-digit royalty on future net sales of the dual-targeting CD19/20 CAR T-cell product in the US.
- Dr. Sumant Ramachandra (former CEO of ImmPACT) appointed to Lyell's Board as a Class III independent director.
Lyell Immunopharma has entered into a definitive agreement to acquire ImmPACT Bio USA Inc. via merger. The transaction involves an upfront payment of $30 million in cash and 37.5 million shares of common stock, plus contingent consideration based on clinical/regulatory milestones.
🚩 Red Flags
- Significant dilution: Issuance of 37.5M shares plus up to 12.5M contingent shares represents substantial equity issuance.
- Pipeline discontinuation: Lyell is discontinuing development of LYL797, LYL845, and several TIL/rejuvenation programs to focus resources.
📋 Key Facts
- Acquisition of ImmPACT Bio USA Inc. via a merger with Inspire Merger Sub Inc.
- Upfront consideration: $30,000,000 cash (subject to adjustment for ~$16M estimated cash balance) and 37,500,000 shares of Lyell common stock.
- Contingent consideration: Up to 12,500,000 additional shares of common stock based on clinical or regulatory milestones.
- Royalty component: Low single-digit royalty on future net sales of the dual-targeting CD19/20 CAR T-cell product in the US.
- ImmPACT stockholders have already approved the merger as of the signing date.
- Lyell will appoint an ImmPACT designee to its board as a Class III director.
Lyell Immunopharma, Inc. filed an 8-K to announce its financial results for the quarter ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Report date: August 7, 2024.
- Reporting period: Quarter ended June 30, 2024.
Lyell Immunopharma reported initial clinical and translational data from its Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell product. The data showed dose-dependent efficacy in patients with advanced solid tumors, specifically TNBC and non-small cell lung cancer.
🚩 Red Flags
- One reported Grade 5 respiratory failure event.
- Significant incidence of pneumonitis (22% overall; 17% Grade ≥ 3) specifically noted in patients with lung metastases.
📋 Key Facts
- Phase 1 trial evaluated LYL797 (ROR1-targeted CAR T-cell) in 20 treated patients (16 TNBC, 4 NSCLC).
- Patients had highly pre-treated metastatic disease with a mean of six prior lines of therapy.
- At the 150 x 10^6 dose level, TNBC patients showed an Objective Response Rate (ORR) of 40% and Clinical Benefit Rate (CBR) of 60%.
- Overall CBR across all evaluable dose levels was 38%.
- Safety data: Most frequent Grade 1/2 adverse event was cytokine release syndrome (61%); most frequent Grade ≥ 3 events were pneumonitis (17%) and hypoxia (11%).
- One instance of Grade 5 respiratory failure reported on Day 41.
- No reports of ICANS attributed to LYL797.
- Translational data showed CAR T-cell expansion, infiltration, and persistence in solid tumors for all evaluable biopsies (n=9).
Lyell Immunopharma held its 2024 annual meeting of stockholders on June 14, 2024. The filing reports the results of shareholder votes regarding director elections, auditor ratification, and executive compensation.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- The Annual Meeting was held virtually on June 14, 2024.
- Quorum was established with 198,815,570 shares present (77.98% of outstanding shares).
- Elizabeth Nabel, M.D. and Lynn Seely, M.D. were elected to the Class III Board of Directors until the 2027 annual meeting.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
- Shareholders approved executive compensation on an advisory basis (Say-on-Pay).
- The record date for the meeting was April 16, 2024.
Lyell Immunopharma, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Reporting period: Quarter ended March 31, 2024.
- Filing date: May 6, 2024.
Lyell Immunopharma, Inc. filed an 8-K to announce its financial results for the quarter and full year ended December 31, 2023.
📋 Key Facts
- Reporting period: Quarter and Full Year ended December 31, 2023.
- Filing date: February 28, 2024.
- The filing includes a press release (Exhibit 99.1) containing the financial results.